A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Details
Age
Adult
Type of Study
Treatment
Locations
Memorial Hospital Central
Memorial Hospital North
Principal Investigator
Rubens Chang
Study ID
Protocol Number: 21-4384
More information available at ClinicalTrials.gov: NCT04879329
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers